Literature DB >> 19754923

A score test for association of a longitudinal marker and an event with missing data.

Dianne M Finkelstein1, Rui Wang, Linda H Ficociello, David A Schoenfeld.   

Abstract

Often clinical studies periodically record information on disease progression as well as results from laboratory studies that are believed to reflect the progressing stages of the disease. A primary aim of such a study is to determine the relationship between the lab measurements and a disease progression. If there were no missing or censored data, these analyses would be straightforward. However, often patients miss visits, and return after their disease has progressed. In this case, not only is their progression time interval censored, but their lab test series is also incomplete. In this article, we propose a simple test for the association between a longitudinal marker and an event time from incomplete data. We derive the test using a very intuitive technique of calculating the expected complete data score conditional on the observed incomplete data (conditional expected score test, CEST). The problem was motivated by data from an observational study of patients with diabetes.
© 2009, The International Biometric Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19754923      PMCID: PMC2952639          DOI: 10.1111/j.1541-0420.2009.01326.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

1.  Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

Authors:  J M Robins; D M Finkelstein
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

2.  Analysis of failure time data with dependent interval censoring.

Authors:  Dianne M Finkelstein; William B Goggins; David A Schoenfeld
Journal:  Biometrics       Date:  2002-06       Impact factor: 2.571

3.  Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study.

Authors:  R B D'Agostino; M L Lee; A J Belanger; L A Cupples; K Anderson; W B Kannel
Journal:  Stat Med       Date:  1990-12       Impact factor: 2.373

4.  A Markov chain Monte Carlo EM algorithm for analyzing interval-censored data under the Cox proportional hazards model.

Authors:  W B Goggins; D M Finkelstein; D A Schoenfeld; A M Zaslavsky
Journal:  Biometrics       Date:  1998-12       Impact factor: 2.571

5.  Model-based approaches to analysing incomplete longitudinal and failure time data.

Authors:  J W Hogan; N M Laird
Journal:  Stat Med       Date:  1997 Jan 15-Feb 15       Impact factor: 2.373

6.  A joint model for survival and longitudinal data measured with error.

Authors:  M S Wulfsohn; A A Tsiatis
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

7.  Applying the Cox proportional hazards model when the change time of a binary time-varying covariate is interval censored.

Authors:  W B Goggins; D M Finkelstein; A M Zaslavsky
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

8.  A proportional hazards model for interval-censored failure time data.

Authors:  D M Finkelstein
Journal:  Biometrics       Date:  1986-12       Impact factor: 2.571

9.  Regression of microalbuminuria in type 1 diabetes.

Authors:  Bruce A Perkins; Linda H Ficociello; Kristen H Silva; Dianne M Finkelstein; James H Warram; Andrzej S Krolewski
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

10.  Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.

Authors:  Linda H Ficociello; Bruce A Perkins; Kristen H Silva; Dianne M Finkelstein; Halina Ignatowska-Switalska; Zbigniew Gaciong; L Adrienne Cupples; Ann Aschengrau; James H Warram; Andrzej S Krolewski
Journal:  Clin J Am Soc Nephrol       Date:  2007-03-27       Impact factor: 8.237

View more
  2 in total

Review 1.  How can we improve clinical trials in amyotrophic lateral sclerosis?

Authors:  Paul H Gordon; Vincent Meininger
Journal:  Nat Rev Neurol       Date:  2011-09-27       Impact factor: 42.937

2.  A joint test for progression and survival with interval-censored data from a cancer clinical trial.

Authors:  Dianne M Finkelstein; David A Schoenfeld
Journal:  Stat Med       Date:  2014-02-06       Impact factor: 2.373

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.